Roche's Avastin Approved For Ovarian Cancer Treatment

BMI View: While the approval of Roche 's Avastin (bevacizumab) as a first-line treatment for ovarian cancer in the Philippines is a positive decision that will moderate the burden of disease, we believe the country's low per capita healthcare and pharmaceutical expenditure put the drug out of reach for the vast majority of the population. In addition, it is also unlikely that Roche will follow GlaxoSmithKline (GSK)'s differential price strategy as the majority of the Swiss company's portfolio contains hard-to-develop biologics.

To read the full article, please choose one of the following options: